Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,956.20
    -583.53 (-0.90%)
     

  • CMC Crypto 200

    1,332.52
    -64.02 (-4.58%)
     

  • S&P 500

    5,105.67
    +57.25 (+1.13%)
     

  • Dow

    38,293.01
    +207.21 (+0.54%)
     

  • Nasdaq

    15,925.00
    +313.25 (+2.01%)
     

  • Gold

    2,351.00
    +8.50 (+0.36%)
     

  • Crude Oil

    83.74
    +0.17 (+0.20%)
     

  • 10-Yr Bond

    4.6710
    -0.0350 (-0.74%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

How Grifols (GRFS) Stock Stands Out in a Strong Industry

Zacks Equity Research

One stock that might be an intriguing choice for investors right now is Grifols, S.A. GRFS. This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Drugs space as it currently has a Zacks Industry Rank of 31 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Grifols is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past two months, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Grifols, S.A. Price and Consensus

Grifols, S.A. Price and Consensus
Grifols, S.A. Price and Consensus

Grifols, S.A. price-consensus-chart | Grifols, S.A. Quote

ADVERTISEMENT

In fact, over the past two months, current quarter estimates have risen from 26 cents per share to 30 cents, while current year estimates have risen from $1.36 per share to $1.41. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Grifols. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Grifols, S.A. (GRFS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.